SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001326190-24-000036
Filing Date
2024-08-15
Accepted
2024-08-15 16:03:03
Documents
14
Period of Report
2024-08-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20240813x8k.htm   iXBRL 8-K 41091
  Complete submission text file 0001326190-24-000036.txt   180523

Data Files

Seq Description Document Type Size
2 EX-101.SCH alt-20240813.xsd EX-101.SCH 3267
3 EX-101.LAB alt-20240813_lab.xml EX-101.LAB 18712
4 EX-101.PRE alt-20240813_pre.xml EX-101.PRE 12845
16 EXTRACTED XBRL INSTANCE DOCUMENT alt-20240813x8k_htm.xml XML 4868
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

IRS No.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 241212324
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)